DiabetologyNews.net

Diabetology Xagena

Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for tr ...


Diabetes is a risk factor for dementia. It is unknown whether higher glucose levels increase the risk of dementia in people without diabetes mellitus.Researchers used 35,264 clinical measurements of g ...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of the study ( INTERVAL ) was to assess the feasibility of ...


Studies have shown that, when implemented early in the course of type 2 diabetes mellitus, treatment with intensive Insulin therapy for 2-3 weeks can induce a glycaemic remission, wherein patients are ...


Effective reduction of albuminuria and blood pressure in patients with type 2 diabetes mellitus who have nephropathy is seldom achieved with available treatments. Researchers tested the effects of tre ...


The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new class of medications called sodium glu ...


The European Medicines Agency ( EMA ) has completed a review of new data on the cancer risk with Insulin glargine-containing medicines. The Agency’s Committee for Medicinal Products for Human Use ( CH ...


New data from a Phase IV study evaluating Linagliptin ( 5 mg ) as monotherapy and in combination with Metformin ( 1500 or 2000 mg ) in treatment-naive adults with newly diagnosed ( less than 12 months ...


The results from a new pooled analysis of phase III data for the dipeptidyl peptidase-4 ( DPP-4 ) inhibitor Linagliptin ( Trajenta ) were presented at the American Diabetes Association ( ADA ) 73rd Sc ...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis ( inflammation of the pancreas ) and preca ...


The results from a new study in which Linagliptin ( Tradjenta ), a DPP-4 inhibitor, has demonstrated statistically significant reductions in blood glucose levels ( HbA1c ) after 12 weeks ( primary end ...


The results of a 52-week phase III clinical trial of Empagliflozin, presented at the American Diabetes Association ( ADA ) 73rd Scientific Sessions, showed statistically significant reductions in HbA1 ...


The results of a 24-week phase III clinical trial, which showed that treatment with the investigational compound Empagliflozin as monotherapy produced statistically significant reductions in HbA1c ver ...


The results of two phase III 24-week clinical trials of the investigational agent Empagliflozin added to Metformin with and without the addition of sulfonylurea, in people with type 2 diabetes ( T2D ) ...


The results from two phase III clinical studies that showed Linagliptin ( Tradjenta ) in Asian adults, as monotherapy and in combination with Metformin, improved blood glucose control in people with t ...